For active psoriatic arthritis (PsA) in adult TNFi‑IR patients¹

Exceptional access is already here. RINVOQ has achieved 99% preferred commercial coverage

PSA patients met ACR20 at Week 12 (Primary Endpoint) and Disease Control through Minimal Disease Activity (MDA) at Week 24 (Ranked Secondary Endpoint), observed up to ~3 years.^3,4

Explore the Data

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

ACR=American College of Rheumatology; ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria (patient assessment of pain, patient global assessment, HAQ-DI, physician global assessment, and hs-CRP); IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

Transcript

Efficacy Results with RINVOQ

Hear from Dr. Evan Siegel, MD, FACP, FACR and Dr. Rachel Tate, DO, FACR about skin and joint efficacy data, safety data, and RINVOQ as an option for adult patients with active PsA who have not achieved their treatment goals on a TNF inhibitor.

RINVOQ EFFICACY DATA

Transcript

Well-Studied Safety Profile

Watch Dr. Evan Siegel, MD, FACP, FACR and Dr. Rachel Tate, DO, FACR discuss the long-term safety profile of RINVOQ across indications—an important consideration prior to prescribing RINVOQ for patients who continue to have symptoms despite previous treatment with a TNF inhibitor.

RINVOQ SAFETY DATA

MEET THE FEATURED PHYSICIANS

RINVOQ met its primary objective ACR20 response
in two clinical studies¹

Significant ACR20 Response at Week 12 (primary endpoint) vs placebo^3,5

SELECT-PsA 2 ACR20 response at Week 12 (NRI)

SELECT-PsA 1 ACR20 response at Week 12 (NRI)

Rapid ACR20 response seen as early as WEEK 2³

SELECT-PsA 2: 33% RINVOQ 15 mg vs 11% placebo (NRI)³

SELECT-PsA 2 Study Design Intro:¹
24‑week, double‑blind, placebo‑controlled study of 642 adult patients with moderately to severely active PsA who had an inadequate response or intolerance to at least one biologic DMARD. Patients were randomized to receive upadacitinib or placebo. The primary endpoint was proportion of patients achieving ACR20 response at Week 12 vs placebo.

SELECT-PsA 1 Study Design Intro:¹
24-week, double‑blind, placebo and active comparator-controlled study of 1705 adult patients with moderately to severely active PsA who had an inadequate response or intolerance to at least one non‑biologic DMARD. Patients were randomized to receive either upadacitinib, active comparator, or placebo. The primary endpoint was proportion of patients achieving ACR20 response at Week 12 vs placebo.

Data Limitations: Week 2 data for all comparisons were not adjusted for multiplicity; therefore, statistical significance has not been established.

ACR=American College of Rheumatology; ACR20=improvement of at least 20% in tender joint count, swollen joint count, and at least 3 other core criteria (patient assessment of pain, patient global assessment, HAQ-DI, physician global assessment, and hs-CRP); DMARD=disease‑modifying antirheumatic drug; IR=intolerance or inadequate response; NRI=nonresponder imputation; QD=once per day; TNFi=tumor necrosis factor inhibitor

RINVOQ is a once-daily JAK inhibitor¹

Rapid Relief³

ACR20 response seen as early as
Week 2

See Joint Efficacy

Durable Control^3,4

Response Rates of:

MDA at Week 24
Joint Efficacy (ACR20/50/70) at Week 12
Skin Efficacy (PASI 75) at Week 16 with data observed up to ~3 years

RINVOQ is not indicated for the treatment of plaque psoriasis

See Disease Control Data

Well-Studied Safety⁶

~5.0 years max. exposure in PsA (~2.9 years median) to RINVOQ 15 mg as of 08/15/22

See Safety Profile

Exceptional Access and Patient Support

>95% preferred national commercial and Medicare Part D formulary coverage under the pharmacy benefit as of September 2023^2,||,¶
1:1 support to help PsA patients start and stay on track with their prescribed treatment plan

See Access & Support

†Clinical experience encompasses the time from first RINVOQ patient dosed in RA clinical trial to present.⁸

‡Includes 2 phase 3 PsA trials, 3 phase 2 trials and 6 phase 3 RA trials, 1 phase 2/3 trial and 1 phase 3 AS trials, 1 phase 3 nr-axSpA trial, 1 phase 2 and 3 phase 3 AD trials, 3 phase 3 UC trials, and 1 phase 2 and 3 phase 3 CD trials. PsA: RINVOQ 15 mg, upadacitinib 30 mg; RA: RINVOQ 15 mg, upadacitinib 30 mg; AS: RINVOQ 15 mg; nr-axSpA: RINVOQ 15 mg; AD: RINVOQ 15 mg and 30 mg; UC: RINVOQ 15 mg, 30 mg, and 45 mg; CD: RINVOQ 15 mg, 30 mg, and 45 mg. RINVOQ 15 mg is the approved dose in RA, PsA, AS, and nr-axSpA; RINVOQ 15 mg and 30 mg are the approved doses in AD; RINVOQ 15 mg, 30 mg and 45 mg are the approved doses in UC and CD.^1,6,7

^§In PsA: ~5.0 years maximum exposure (~2.9 years median) to RINVOQ 15 mg as of 08/2022; In AS: ~3.8 years maximum exposure (~1.7 years median) to RINVOQ 15 mg as of 08/2022. In nr-axSpA: ~2.4 years maximum exposure (~1.0 years median) to RINVOQ 15 mg as of 08/2022.⁶

^||RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.

^¶Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

ACR20/50/70=improvement of at least 20%/50%/70% in tender joint count, swollen joint count, and at least 3 other core criteria (patient assessment of pain, patient global assessment, HAQ-DI, physician global assessment, and hs-CRP); AD=atopic dermatitis; AS=ankylosing spondylitis; CD=Crohn's disease; DMARD=disease-modifying antirheumatic drug; IR=intolerance or inadequate response; LDI=Leeds dactylitis index; LEI=Leeds enthesitis index; max.=maximum; mTSS=modified total Sharp score; nr-axSpA=non-radiographic axial spondyloarthritis; PASI 75=at least 75% reduction in psoriasis area severity score from baseline; RA=rheumatoid arthritis; TNFi=tumor necrosis factor inhibitor; UC=ulcerative colitis

Join an upcoming educational speaker program webinar

EXPLORE NOW

To achieve an ACR20, 50, or 70 response, a patient must have at least a 20%, 50%, or 70%, respectively, improvement in tender and swollen joint counts and three of five scores of individual elements:

patient pain;
physician's global assessment of disease activity;
patient's global assessment;
physical function (HAQ-DI);
and an acute phase reactant (hs‑CRP).

IMPROVEMENTS IN ACR COMPONENTS OF DISEASE ACTIVITY IN SELECT-PsA 2²

IMPROVEMENTS IN ACR
COMPONENTS OF DISEASE
ACTIVITY IN SELECT-PsA 2²

SELECT-PsA 2: ACR Components of Disease Activity

^aNumeric rating scale (NRS) from 0=best, to 10=worst
^bHealth Assessment Questionnaire Disability Index ranked from 0=best, to 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities

ACR=American College of Rheumatology; HAQ‑DI=health assessment questionnaire disability index; hs‑CRP=high‑sensitivity C‑reactive protein; NRS=numeric rating scale; QD=once per day; SD=standard deviation; ULN=upper limit of normal

REFERENCES

US-MULT-221361

RINVOQ met its primary objective ACR20 response in two clinical studies1

RINVOQ is a once-daily JAK inhibitor1

Rapid Relief3

Durable Control3,4

Well-Studied Safety6

Exceptional Access and Patient Support

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATIONS1

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)

SERIOUS INFECTIONS

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

MEDICATION RESIDUE IN STOOL

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS

SELECT‑PsA 2

SELECT‑PsA 1

SELECT‑PsA 1

SELECT‑PsA 2

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATIONS1

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)

SERIOUS INFECTIONS

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

MEDICATION RESIDUE IN STOOL

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS

INDICATIONS & LIMITATION OF USE1

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

INDICATIONS & LIMITATION OF USE1

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATIONS1

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)

SERIOUS INFECTIONS

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

MEDICATION RESIDUE IN STOOL

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS

RINVOQ met its primary objective ACR20 response
in two clinical studies¹

RINVOQ is a once-daily JAK inhibitor¹

Rapid Relief³

Durable Control^3,4

Well-Studied Safety⁶

IMPORTANT SAFETY INFORMATION & INDICATIONS¹

INDICATIONS¹

IMPORTANT SAFETY INFORMATION & INDICATIONS¹

INDICATIONS¹

INDICATIONS & LIMITATION OF USE¹

IMPORTANT SAFETY INFORMATION¹

IMPORTANT SAFETY INFORMATION¹

INDICATIONS & LIMITATION OF USE¹

IMPORTANT SAFETY INFORMATION¹

IMPORTANT SAFETY INFORMATION¹

IMPORTANT SAFETY INFORMATION & INDICATIONS¹

INDICATIONS¹